시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 항헤마글루티닌(Ha) 항체 시장 보고서(2025년)
Anti Hemagglutinin (Ha) Antibody Global Market Report 2025
상품코드 : 1889296
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,586,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,520,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,454,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

항헤마글루티닌(Ha) 항체 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 15억 달러로 평가되었고, 2025년에는 16억 6,000만 달러에 달할 것으로 추정되며, CAGR 10.7%로 성장할 전망입니다. 지금까지의 성장은 바이러스 연구에서 항체의 이용 증가, 백신 개발에서 신뢰성 높은 검출 툴에 대한 수요 증가, 인플루엔자 및 바이러스 단백질 연구에 대한 주목의 강화, 생물 의료 및 면역학 연구에 대한 자금 확충, 실험실 환경에서 표지 단백질 분석의 보급 확대에 기인한 것으로 보입니다.

항헤마글루티닌(Ha) 항체 시장 규모는 향후 수년간 급속한 성장이 예상됩니다. 2029년에는 24억 5,000만 달러에 달할 것으로 예측되며, CAGR 10.3%로 성장할 전망입니다. 예측 기간에 있어서의 성장요인으로는, 진단 검정에서 항Ha항체의 이용확대, 연구기관 및 바이오테크놀러지 기업 간 제휴 강화, 항체 기반 검출 기술의 인지도 향상, 첨단 항체 생산 기술의 보급, 표적 항바이러스 요법 개발에 대한 관심 증가 등을 들 수 있습니다. 예측 기간 동안 예상되는 주요 동향으로는 재조합 항체 공학의 진보, 진단 분석 개발의 혁신, 항체 스크리닝에 AI 및 자동화의 통합, 고성능 항체 생산 플랫폼의 진전, 항바이러스 치료 연구에서의 지속적인 혁신 등을 들 수 있습니다.

인플루엔자의 만연 확대는 향후 항헤마글루티닌(HA) 항체 시장의 성장을 이끌 것으로 예측됩니다. 인플루엔자는 감염력이 강한 호흡기 바이러스 감염(감기)이며, 발열, 기침, 목 통증, 전신 통증 등의 증상을 일으키며, 그 정도는 경도에서 중증까지 다양합니다. 인플루엔자의 확산 확장은 주로 빈번한 국제 이동으로 인해 바이러스가 국경을 넘어 빠르게 전파되기 때문입니다. 항헤마글루티닌(HA) 항체는 바이러스의 HA 단백질을 특이적으로 표적으로 함으로써 인플루엔자의 관리를 지원하고 진단, 연구 개발, 백신 개발에 유용합니다. 이들 항체는 인플루엔자 감염의 정확한 검출 및 모니터링을 가능하게 하고 효과적인 질병 관리 및 예방을 지원함으로써 치료 전략을 강화합니다. 예를 들어, 2025년 2월에 세계보건기구(WHO)가 보고한 바에 의하면, 계절성 인플루엔자는 세계에서 약 10억 명에 영향을 미치고, 연간 300만-500만 건의 중증례와 29만-65만 건의 호흡기 관련 사망을 일으키고 있습니다. 이 결과, 인플루엔자 증가 경향이 항혈구 응집소(HA) 항체 시장의 성장을 가속하고 있습니다.

항헤마글루티닌(HA) 항체 시장의 주요 기업들은 백신 효능과 항체 반응을 평가하기 위한 보다 안전하고 정밀한 바이러스-유사 모델을 개발하기 위해 진짜 바이러스 구조와 같은 첨단 기술 혁신에 주력하고 있습니다. 진짜 바이러스 구조는 유전 물질을 포함하지 않고 생 바이러스의 자연적인 구성과 표면 단백질을 충실하게 모방한 구조 설계를 말합니다. 예를 들어, 2023년 11월에는 미국 바이오테크놀러지 기업 인테그럴 모레큘러사가 원 인플루엔자 바이러스의 대체가 되는 기성 및 비감염성의 'TiterSafe 인플루엔자 바이러스 유사 입자'를 발표했습니다. 이 진정한 바이러스 구조를 통해 연구자는 인플루엔자 백신 효능 평가의 FDA 승인 기준인 혈구 응집 억제 검사(HAI)를 안전하게 수행할 수 있습니다. TiterSafe는 감염성 바이러스의 배양과 특수 바이오 세이프티 시설의 필요성을 제거하고 실험실 위험을 크게 줄입니다. 이 입자군은 헤마글루티닌(HA)과 뉴라미니다제(NA)와 같은 표면 단백질을 가진 생 바이러스의 구조를 재현하여 정확한 실험 결과를 보장합니다. 이 혁신 기술은 실험실의 안전성 및 워크플로우 효율을 향상시키면서 높은 처리량과 신뢰성 있는 인플루엔자 항체 검사를 지원합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Anti-hemagglutinin (Ha) antibody is an immunoglobulin designed to specifically recognize and bind to the hemagglutinin (Ha) protein found on the surface of influenza viruses or on Ha-tagged recombinant proteins. It is widely used in research and diagnostic applications to detect, measure, or isolate Ha-containing proteins. These antibodies play an important role in virology, vaccine development, and molecular biology experiments involving tagged protein expression systems.

The primary product types in the anti-hemagglutinin (Ha) antibody market include monoclonal antibodies, polyclonal antibodies, and recombinant antibodies. Monoclonal antibodies are laboratory-engineered molecules that bind precisely to the hemagglutinin (Ha) antigen of influenza viruses, allowing accurate detection, quantification, and neutralization in research, diagnostic, and therapeutic settings. They employ technologies such as ELISA-based methods, flow cytometry, immunohistochemistry, and Western blotting, and are derived from sources including mouse, rabbit, goat, and chicken. Key applications include research, diagnostics, and therapeutics, serving end-users such as academic research institutes, biotechnology firms, pharmaceutical companies, and diagnostic laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The anti hemagglutinin (Ha) antibody market research report is one of a series of new reports from The Business Research Company that provides anti hemagglutinin (Ha) antibody market statistics, including the anti hemagglutinin (Ha) antibody industry global market size, regional shares, competitors with the anti hemagglutinin (Ha) antibody market share, detailed anti hemagglutinin (Ha) antibody market segments, market trends, and opportunities, and any further data you may need to thrive in the anti hemagglutinin (Ha) antibody industry. This anti hemagglutinin (Ha) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anti hemagglutinin (Ha) antibody market size has grown rapidly in recent years. It will grow from $1.50 billion in 2024 to $1.66 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. Growth in the historic period can be attributed to the increasing use of antibodies in viral research, rising demand for reliable detection tools in vaccine development, greater focus on influenza and viral protein studies, expanding funding for biomedical and immunology research, and the growing adoption of tagged protein analysis in laboratory settings.

The anti hemagglutinin (Ha) antibody market size is expected to see rapid growth in the next few years. It will grow to $2.45 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. Growth in the forecast period can be attributed to the expanding use of anti-Ha antibodies in diagnostic assays, increasing collaboration between research institutions and biotechnology companies, rising awareness of antibody-based detection techniques, growing use of advanced antibody production technologies, and heightened interest in developing targeted antiviral therapies. Major trends expected in the forecast period include advancements in recombinant antibody engineering, innovations in diagnostic assay development, the integration of AI and automation in antibody screening, progress in high-throughput antibody production platforms, and continued innovation in antiviral therapeutic research.

The increasing prevalence of influenza is expected to drive the growth of the anti-hemagglutinin (HA) antibody market moving forward. Influenza is a highly contagious respiratory viral infection (the flu), causing symptoms such as fever, cough, sore throat, and body aches, which can vary from mild to severe. The rising prevalence of influenza is largely due to frequent international travel, which allows for rapid cross-border transmission of the virus. Anti-hemagglutinin (HA) antibodies aid in influenza management by specifically targeting the viral HA protein, making them valuable for diagnostics, research, and vaccine development. These antibodies enhance treatment strategies by enabling accurate detection and monitoring of influenza infections, supporting effective disease control and prevention. For example, in February 2025, the World Health Organization (WHO) reported that seasonal influenza affects approximately one billion people globally, leading to 3-5 million severe cases and causing 290,000 to 650,000 respiratory-related deaths annually. As a result, the increasing prevalence of influenza is driving growth in the anti-hemagglutinin (HA) antibody market.

Major companies in the anti-hemagglutinin (HA) antibody market are focusing on advanced innovations, such as authentic virus architecture, to develop safer and more precise virus-like models for evaluating vaccine efficacy and antibody responses. Authentic virus architecture refers to the structural design that closely mimics the natural composition and surface proteins of a live virus, without containing its genetic material. For instance, in November 2023, Integral Molecular, a US-based biotechnology company, launched TiterSafe influenza virus-like particles as an off-the-shelf, non-infectious alternative to live influenza virus. This authentic virus architecture allows researchers to safely conduct hemagglutination inhibition (HAI) assays, the FDA-approved standard for assessing influenza vaccine effectiveness. TiterSafe eliminates the need for culturing infectious viruses or using specialized biosafety facilities, reducing laboratory risks significantly. The particles replicate the structure of live viruses with surface proteins like hemagglutinin (HA) and neuraminidase (NA), ensuring accurate experimental results. This innovation supports high-throughput, reliable influenza antibody testing while improving laboratory safety and workflow efficiency.

In August 2023, Danaher Corporation, a US-based science and technology company, acquired Abcam plc for an undisclosed amount. Through this acquisition, Danaher aims to expand its presence in the life sciences and biopharmaceutical research sectors by strengthening its portfolio of high-quality antibodies, reagents, and protein consumables, enhancing its ability to support drug discovery, disease mapping, and diagnostic innovation using Abcam's extensive product range and scientific expertise. Abcam plc, a UK-based biotechnology company, is renowned for its production of anti-hemagglutinin (HA) antibodies.

Major companies operating in the anti hemagglutinin (ha) antibody market are Johnson & Johnson, F. Hoffmann-La Roche AG, Pfizer Inc., AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Amgen Inc., Merck KGaA, Danaher Corporation, Bio-Rad Laboratories Inc., Bio-Techne Corporation, GenScript Biotech Corporation, Sino Biological Inc., Cell Signaling Technology Inc., Proteintech Group Inc., Santa Cruz Biotechnology Inc., Integral Molecular, Rockland Immunochemicals Inc., Biorbyt Ltd.

North America was the largest region in the anti hemagglutinin (Ha) antibody market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti hemagglutinin (Ha) antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anti hemagglutinin (Ha) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti hemagglutinin (Ha) antibody market consists of revenues earned by entities by providing services such as quality control and validation services, regulatory consulting services, and custom antibody generation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The anti-HA antibody market also includes sales of Western blot reagents, immunohistochemistry (IHC) kits, flow cytometry reagents, immunoprecipitation kits, cell culture media, and purification columns. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti Hemagglutinin (Ha) Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti hemagglutinin (ha) antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for anti hemagglutinin (ha) antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anti hemagglutinin (ha) antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Anti Hemagglutinin (Ha) Antibody Market Characteristics

3. Anti Hemagglutinin (Ha) Antibody Market Trends And Strategies

4. Anti Hemagglutinin (Ha) Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Anti Hemagglutinin (Ha) Antibody Growth Analysis And Strategic Analysis Framework

6. Anti Hemagglutinin (Ha) Antibody Market Segmentation

7. Anti Hemagglutinin (Ha) Antibody Market Regional And Country Analysis

8. Asia-Pacific Anti Hemagglutinin (Ha) Antibody Market

9. China Anti Hemagglutinin (Ha) Antibody Market

10. India Anti Hemagglutinin (Ha) Antibody Market

11. Japan Anti Hemagglutinin (Ha) Antibody Market

12. Australia Anti Hemagglutinin (Ha) Antibody Market

13. Indonesia Anti Hemagglutinin (Ha) Antibody Market

14. South Korea Anti Hemagglutinin (Ha) Antibody Market

15. Western Europe Anti Hemagglutinin (Ha) Antibody Market

16. UK Anti Hemagglutinin (Ha) Antibody Market

17. Germany Anti Hemagglutinin (Ha) Antibody Market

18. France Anti Hemagglutinin (Ha) Antibody Market

19. Italy Anti Hemagglutinin (Ha) Antibody Market

20. Spain Anti Hemagglutinin (Ha) Antibody Market

21. Eastern Europe Anti Hemagglutinin (Ha) Antibody Market

22. Russia Anti Hemagglutinin (Ha) Antibody Market

23. North America Anti Hemagglutinin (Ha) Antibody Market

24. USA Anti Hemagglutinin (Ha) Antibody Market

25. Canada Anti Hemagglutinin (Ha) Antibody Market

26. South America Anti Hemagglutinin (Ha) Antibody Market

27. Brazil Anti Hemagglutinin (Ha) Antibody Market

28. Middle East Anti Hemagglutinin (Ha) Antibody Market

29. Africa Anti Hemagglutinin (Ha) Antibody Market

30. Anti Hemagglutinin (Ha) Antibody Market Competitive Landscape And Company Profiles

31. Anti Hemagglutinin (Ha) Antibody Market Other Major And Innovative Companies

32. Global Anti Hemagglutinin (Ha) Antibody Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti Hemagglutinin (Ha) Antibody Market

34. Recent Developments In The Anti Hemagglutinin (Ha) Antibody Market

35. Anti Hemagglutinin (Ha) Antibody Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기